ClinicalTrials.gg
RecruitingNCT06819254Updated Nov 20, 2026

Pilot Study of Fisetin to Improve Fatigue Among Older Adult Cancer Survivors

A Phase 4 interventional study of Fisetin followed by Placebo and Placebo followed by Fisetin in Fatigue, sponsored by Wake Forest University Health Sciences. Recruiting at 1 site in United States. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Wake Forest University Health Sciences · Phase 4, Interventional, and Other

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Nov 20, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Fatigue by Wake Forest University Health Sciences — 2 open to participants now, 3 under way, none of them phase 3. Fatigue · Wake Forest University Health Sciences.

Planned enrollment
9th of 16
60 · median 61
Started
2025
with 1 other
Phase 4
Only one
of the 20
Registered
20th of 20
by date

Among the 20 studies in Fatigue by Wake Forest University Health Sciences, this one is the 9th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2025, is the only one in phase 4, and was the 20th registered.

Fatigue

2,234 studies on the registry are indexed under Fatigue; 430 are open to participants now.

Browse Fatigue studies →

Open to participants now

2 of the 20 studies in Fatigue by Wake Forest University Health Sciences are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 242 Fatigue studies recruiting now, 113 (47%) set no upper age limit and 99 (41%) stop at 75 or younger; 23 take children under 18; 74 take healthy volunteers.

This study: 65 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Fatigue by Wake Forest University Health Sciences, or all of them as a file.
02

Study summary

The purpose of this study is to find out if taking a Fisetin supplement can decrease fatigue among older cancer survivors.

Read the detailed description

Prospective double-blind placebo controlled, 14-day cross-over trial of patients aged 65 and over with a history of cancer with self-reported fatigue. Participants will be randomized and provided with Fisetin pills or placebo to take twice daily on two consecutive days for two consecutive weeks. Participants will return on day 14 for a blood draw followed by a 14 day wash-out. At the four-week visit participants will receive a cross-over placebo-controlled dosing regimen over two weeks. Follow-up phone calls for safety assessment and adherence review will occur at weeks 1 and 5. Follow-up assessments will be completed at 2, 4 and 6 weeks, and a post-treatment phone call assessment completed at 12 weeks.

03

Conditions studied

  • Fatigue

Browse trials for

Keywords

  • cancer survivor
  • supplement
  • Fisetin
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Self-reported history of cancer diagnosed > 12 months prior to enrollment excluding non-melanoma skin cancer with no evidence of disease at enrollment.
  • Eligible solid tumor cancer types include Stage 1-3 breast, lung, head and neck, colorectal, anal, prostate, melanoma, bladder/ureteral, esophageal, gastric, pancreatic, kidney, liver/biliary, uterine, cervical, ovarian, sarcoma. (superficial disease and in situ disease only is excluded)
  • Eligible hematologic include lymphoma any subtype any stage in remission, multiple myeloma in remission, leukemia any subtype in remission.
  • Eligible prior cancer treatment modalities include surgery, radiation, chemotherapy, hormonal therapies, immunotherapy, biologic therapies.
  • All anti-cancer therapy completed > 6 months prior to enrollment with \< 5 years from treatment
  • Presence of self-reported fatigue defined by a response of "somewhat, quite a bit, or very much" to the screening question "During the past seven days, did you feel fatigued: Not at all, a little bit, somewhat, quite a bit, very much?"
  • Ability to walk without requiring assistance from another individual (use of cane or walker acceptable)
  • Ability to understand and the willingness to sign an IRB-approved document (either directly or via a legally authorized representative).

Exclusion criteria

Exclusion Criteria:

  • Unable or unwilling to give
  • Female patients are of , defined as for at least 1 year.
  • Prisoners, institutionalized individuals, or others who may be considered vulnerable populations, such as individuals with dementia
  • Currently taking warfarin or Coumadin
  • Currently taking a medication either regularly or within the last two weeks.
  • Patients currently taking medications that are sensitive to substrates or substrates with a narrow therapeutic range for CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, , OATP1B1 (Unless willing and able to stop or modify the dosing of the drug) or strong inhibitors or inducers of CYP3A4 (e.g., cyclosporine, tacrolimus, or sirolimus) are excluded, unless medication can be safely held during the following times:
  • Immediately before the 1st IP administration (Day 0 or Day 30) until at least 10 hours after the 2nd IP administration (Day 1 or Day 31)
  • Immediately before the 3rd IP administration (Day 7 or Day 37) until at least 10 hours after the 4th IP administration (Day 8 or Day 38)
  • Subjects taking any of the medications listed in Appendix I may participate if they are otherwise eligible AND the medication can be safely held during the following times: Immediately before the 1st IP administration (Day 0 or Day 30) until at least 10 hours after the 2nd IP administration (Day 1 or Day 31); Immediately before the 3rd IP administration (Day 7 or Day 37) until at least 10 hours after the 4th IP administration (Day 8 or Day 38)
  • Drugs listed as part of the exclusion criteria are not permitted during each of the two 2-day courses of treatment with Fisetin. If patients are required to initiate these medications within the 2-day period, they will be removed from the study primarily due to risk of drug-drug interaction.
  • Uncontrolled hypertension (systolic >170 OR diastolic >100 mmHg) upon repeated assessments
  • Uncontrolled (as per clinical judgement) pleural/pericardial effusions or ascites
  • Active or on-going cancer treatment including oral anti-estrogen therapy, immunotherapy, biologic therapy.
  • Men receiving androgen deprivation therapy
  • Symptomatic congestive heart failure
  • Lung disease requiring oxygen
  • End stage renal disease requiring dialysis
  • Inability to swallow capsules
  • Chronic nausea or diarrhea defined by a frequency of ≥ once per week
  • Diagnosis of dementia
  • Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Known untreated hypothyroidism
  • Allergy to fisetin
  • infection
  • Known active untreated or C infection
  • Active invasive fungal infection
  • Unwilling to provide informed consent, including consent to access electronic health records
  • Judged unsuitable for the trial for any reason by research team
  • The following laboratory tests as indicated or as per clinical judgement: Normal organ and marrow function as defined: \<10g/dL, leukocytes \<3,000/mcL, \<1,500/mcL, \<100,000/mcL, total above normal institutional limits, (SGOT)/ALT(SGPT) >2.5 X institutional , \<30 mL/min, fasting glucose >300 on day of screening (from plasma or serum)
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Fisetin - Placebo

    Two-week regimen of Fisetin supplement followed by two-week regimen of placebo.

    Drug: Fisetin followed by Placebo

  • Experimental
    Placebo - Fisetin

    Two-week regimen of placebo followed by two-week regimen of Fisetin supplement.

    Drug: Placebo followed by Fisetin

Interventions

  • DrugFisetin followed by Placebo

    Fisetin 20 mg/kg per dose twice daily on two consecutive days for two consecutive weeks. Participants will return on day 14 for a blood draw followed by a 14-day wash-out. At the 4-week visit participants will receive a cross-over placebo-controlled dosing regimen to be taken twice daily on two consecutive days for two consecutive weeks.

  • DrugPlacebo followed by Fisetin

    Placebo twice daily on two consecutive days for two consecutive weeks. Participants will return on day 14 for a blood draw followed by a 14-day wash-out. At the 4-week visit participants will receive a cross-over Fisetin 20 mg/kg per dose twice daily on two consecutive days for two consecutive weeks.

06

What researchers measure

Primary outcomes

  1. Change in Pittsburgh Fatigability Scale (PFS)

    10-item PFS score is a measure of perceived fatigability in older adults and can serve as an adjunct to performance-based fatigability measures for identifying older adults at risk of mobility limitation in clinical and research settings. Total score range is 0-50 with higher score indicating greater fatigue.

    Time frame: Baseline to Week 2

  2. Change in Pittsburgh Fatigability Scale (PFS)

    10-item PFS score is a measure of perceived fatigability in older adults and can serve as an adjunct to performance-based fatigability measures for identifying older adults at risk of mobility limitation in clinical and research settings. Total score range is 0-50 with higher score indicating greater fatigue.

    Time frame: Baseline to Week 4

  3. Change in Pittsburgh Fatigability Scale (PFS)

    10-item PFS score is a measure of perceived fatigability in older adults and can serve as an adjunct to performance-based fatigability measures for identifying older adults at risk of mobility limitation in clinical and research settings. Total score range is 0-50 with higher score indicating greater fatigue.

    Time frame: Baseline to Week 6

  4. Change in Pittsburgh Fatigability Scale (PFS)

    10-item PFS score is a measure of perceived fatigability in older adults and can serve as an adjunct to performance-based fatigability measures for identifying older adults at risk of mobility limitation in clinical and research settings. Total score range is 0-50 with higher score indicating greater fatigue.

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Change in Patient Reported Outcomes Measurement System (PROMIS)

    PROMIS Fatigue Short-Form 7a - Item responses are rated on a five-point scale ranging from "never" to "always." Total score range is 5-35 with a higher scores indicating more fatigue.

    Time frame: Baseline to Week 2, Baseline to Week 4, Baseline to Week 6, Baseline to Week 12

  2. Change in Pepper Assessment Tool for Disability (PAT-D)

    The (PAT-D) is a 19-item survey to assess domains of physical function in older adults. Responses are made on a five-point Likert scale ranging from "usually did with no difficulty" to "unable to do." Total score range is 19-95 with lower scores indicating better mobility and ability to perform activities of daily and instrumental activities of daily living.

    Time frame: Baseline to Week 2, Baseline to Week 4, Baseline to Week 6

  3. Change in Expanded Short Physical Performance Battery (eSPPB)

    eSPPB is used to objectively assess lower extremity physical function. This validated measure comprises a short walk, narrow walk, repeated chair stands, and balance tests. Total score range is 0-12 with higher scores indicating better physical performance. Lower scores on the eSPPB have been associated with increased risk of disability, hospitalization and worse survival among older adults with and without cancer.

    Time frame: Baseline to Week 2, Baseline to Week 4, Baseline to Week 6

  4. Change in 6-minute Walk Distance

    Distance participant is able to walk in 6-minute will be measured. The 6-minute walk accurately assesses submaximal exercise capacity and is an independent predictor of mortality and is correlated with peak V02 testing.

    Time frame: Baseline to Week 2, Baseline to Week 4, Baseline to Week 6

  5. Change in Fried Frailty Phenotype Score

    Frailty score is calculated using the Frailty Index Calculation form. Score range is 0-5 with a higher score indicating frailty.

    Time frame: Baseline to Week 2, Baseline to Week 4, Baseline to Week 6

  6. Change in Longitudinal Aging Study Amsterdam (LASA) Sedentary Behavior Questionnaire

    10-item questionnaire used to measure sedentary behavior. The average time per 24 hours spent on each individual sedentary activity will be recorded in hours and/or minutes. This will be done for an average weekday as well as for an average weekend day. Ranges from 0-24 hours with a higher score indicating more sedentary behavior.

    Time frame: Baseline to Week 2, Baseline to Week 4, Baseline to Week 6

  7. Change in PROMIS Global Health Short Form

    PROMIS Global Health Short Form is a 10-item instrument assesses the extent to which patients experience problems with fatigue over the past 7 days using a 5-point Likert scale. The fatigue subscale provides a raw score, ranging from 4 to 20. Raw scores are converted to T-scores using the PROMIS conversion tables. Higher scores reflect greater fatigue.

    Time frame: Baseline to Week 2, Baseline to Week 4, Baseline to Week 6

  8. Medication Adherence Rate

    Empty bottles from home will be returned. The number of pills taken is calculated by subtracting the count of the number of pills remaining from the total number of pills dispensed. The drug adherence rate is then calculated by dividing the number of pills taken by the number of pills they were supposed to take.

    Time frame: Week 2, Week 5

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2027, 24 months after the start.

Of 15 phase 4 interventional studies under Fatigue, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 55. This study's planned 24 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Dec 2026 → Dec 2027 and completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2025
First posted
Feb 11, 2025
StartActual
Dec 9, 2025
Primary completionEst.
Dec 31, 2027was Dec 2026
CompletionEst.
Dec 31, 2027was Dec 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2026→Dec 31, 2027
Nov 20, 2026
Study completion
Dec 31, 2026→Dec 31, 2027
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Primary completion Dec 31, 2026→Dec 31, 2027
    Study completion Dec 31, 2026→Dec 31, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06819254
Collaborators
The Ambrose Monell Foundation
Responsible party
Sponsor
First posted
Feb 11, 2025
Start date
Dec 9, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 20, 2026

Study contacts

Kimberly Kennedy
Contact
kkennedy@wakehealth.edu
336-713-8567
Stephen Kritchevsky, PhD
principal investigator · Wake Forest University Health Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion